Company Buyout Price: Tiziana Life Sciences, Ltd. (TLSA)
The market price visualization for Tiziana Life Sciences (TLSA) on the GURU.Markets platform shows the enterprise value at 100.40. Tiziana Life Sciences focuses on developing targeted antibodies for oncology and severe inflammation. The approval of foralumab will provide the company with pricing power due to its unique nasal drug delivery method to the brain. Meanwhile, the company optimizes R&D costs by effectively outsourcing manufacturing processes to third-party contractors.
%3A%20Enterprise%20Value&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261031&filename=GURU_Markets_-_TLSA_-_Tiziana-Life-Sciences_-_Enterprise-Value "Tiziana Life Sciences Ltd - TLSA Enterprise Value (period 11/23/2025 - 10/31/2026) | 👁️GURU.Markets👁️")
Tiziana Life Sciences (TLSA) - metric breakdowns and financial figures
- stock price and consensus target price:
- company stock exchange capitalization indicators:
- balance sheet equity data:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Tiziana Life Sciences|TLSA - Long-Term Debt to Capital|Short-Term Debt to Capital tizianalifesciences.com|TLSA - Company Debts|Debt to Net Assets Ratio Tiziana Life Sciences|TLSA - Company Long-Term Debt|Company Current Liabilities Tiziana Life Sciences|Quick Ratio tizianalifesciences.com
- business earnings and investment ratios data:
Analysis of all company metrics:Tiziana Life Sciences Ltd.
Enterprise Value (EV) represents the total buyout price of a business, combining market capitalization and net debt to eliminate the impact of leverage. The current value of 100.40 on this enterprise value chart reflects Tiziana Life Sciences (TLSA) high dependence on existing reserves, which are rapidly depleting due to costly immunological developments, rendering the asset sensitive to liquidity shortages.
Competitors of Tiziana Life Sciences (TLSA)
argenx N.V. - Total Company Value|BNTX - Total Company Value|Company Buyout Price Abivax Pharma ABVX|ADMA: Enterprise Value|protagonist-inc.com (PTGX) - Enterprise Value|Total Company Value Immunovant|Kiniksa Pharmaceuticals, Ltd. - Full Business Value|Enterprise Value GRFS|ADPT (Adaptive Biotechnologies Inc.) - Value Adjusted for Debt and Cash|Enterprise Value CLDX (Celldex Therapeutics)|Enterprise Value auriniapharma.com AUPH|BCRX - Total Company Value|Value Adjusted for Debt and Cash VERA (Vera Therapeutics Inc)|Dianthus Pharma (DNTH) - Total Company Value|Real Price to Acquire Entire Company Pharvaris Pharma|ABCL (AbCellera Biologics Inc) - Enterprise Value|Enterprise Value tourmalinebio.com|Real Price to Acquire Entire Company PGEN (Precigen)|PHAR (Pharming Group NV) - Value Adjusted for Debt and Cash|Enterprise Value NKTR (Nektar)|Company Buyout Price Upstream Pharma (UPB)|ZBIO - Total Company Value|immunome.com (IMNM) - Real Price to Acquire Entire Company|Gossamer Bio (GOSS) - Total Company Value|Real Price to Acquire Entire Company KalVista Pharma|Real Price to Acquire Entire Company SEPN|Enterprise Value Pieris Corp|Total Company Value Savara Inc. (SVRA)|rigel.com - Business Value|Enterprise Value ANAB (AnaptysBio)|Astria Therapeutics Inc (ATXS) - Total Enterprise Value|ENGN: Real Price to Acquire Entire Company|RAPT Therapeutics Inc. - Aggregate Business Value|JBIO: Enterprise Value|ACRS - Company Buyout Price|Real Price to Acquire Entire Company KYTX|Cabaletta Bio Inc. - Full Business Value|Enterprise Value VTYX|Company Buyout Price Theratechnologies, Inc|Enterprise Value AVTX (Avalo Therapeutics, Inc)|Enterprise Value eledon.com ELDN|AGEN - Total Company Value|CLYM (Climb Bio Inc.) - Business Value|ZURA: Enterprise Value|aTyr Pharmaceuticals (ATYR) - Enterprise Value|Real Price to Acquire Entire Company ADAG|IMA: Value Adjusted for Debt and Cash|Total Company Value Shattuck Labs, Inc. (STTK)|Total Company Value EQ (equilliumbio.com)|Enterprise Value CNTB (Connect Biopharma Holdings Limited)|Company Buyout Price Immunic Therapeutics (IMUX)|Atara Biotherapeutics Inc - Enterprise Value|Full Business Value IFRX|XFOR: Enterprise Value|Total Enterprise Value Adicet Bio, Inc. (ACET)|Real Price to Acquire Entire Company CELU|INMB: Value Adjusted for Debt and Cash|Total Company Value Barinthus Biotherapeutics (BRNS)|Company Buyout Price kezarlifesciences.com|Enterprise Value SABS (SAB Biotherapeutics, Inc.)|AKTX - Real Price to Acquire Entire Company|Enlivex Therapeutics, Ltd. - Enterprise Value|Company Buyout Price Q32 Bio Inc. QTTB|GOVX: Enterprise Value|Total Enterprise Value edesabiotech.com (EDSA)|Total Company Value iBio|Business Value CARM (Carisma Tx)|Enterprise Value XTLB|Real Price to Acquire Entire Company boltbio.com BOLT|Enterprise Value HCWB (HCW Biologics)|Aptevo Therapeutics, Inc. (APVO) - Total Enterprise Value|AIM - Total Company Value|Company Buyout Price Aditxt ADTX|GRI (GRI Bio Corp) - Real Price to Acquire Entire Company|XRTX: Aggregate Business Value|Total Company Value Vyome Holdings Inc|Total Company Value REVB|Total Company Value Indaptus Therapeutics, Inc. (INDP)|Company Buyout Price Scinai Immunotherapeutics Ltd|Enterprise Value CALI (CalciMedica)|Enterprise Value Affimed NV AFMD|ALLK - Total Company Value|Full Business Value HOOK|IGMS: Enterprise Value|iTeos Therapeutics Inc - Value Adjusted for Debt and Cash|OCEA (Ocean Bio) - Enterprise Value|Enterprise Value TC BioPharm Ltd|Total Company Value Third Harmonic Bio (THRD)